BeiGene, Ltd. (BEIGF)
OTCMKTS · Delayed Price · Currency is USD
15.50
0.00 (0.00%)
At close: Nov 11, 2024

BeiGene Statistics

Total Valuation

BeiGene has a market cap or net worth of 20.64 billion. The enterprise value is 18.98 billion.

Market Cap 20.64B
Enterprise Value 18.98B

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date Nov 13, 2024
Ex-Dividend Date n/a

Share Statistics

Current Share Class n/a
Shares Outstanding n/a
Shares Change (YoY) -0.07%
Shares Change (QoQ) +0.26%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 57.41M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -22.21
EV / Sales 5.66
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -15.93

Financial Position

The company has a current ratio of 1.94, with a Debt / Equity ratio of 0.31.

Current Ratio 1.94
Quick Ratio 1.64
Debt / Equity 0.31
Debt / EBITDA n/a
Debt / FCF -0.88
Interest Coverage -57.74

Financial Efficiency

Return on equity (ROE) is -23.22% and return on invested capital (ROIC) is -12.29%.

Return on Equity (ROE) -23.22%
Return on Assets (ROA) -9.58%
Return on Capital (ROIC) -12.29%
Revenue Per Employee 316,161
Profits Per Employee -80,606
Employee Count 10,600
Asset Turnover 0.58
Inventory Turnover 1.44

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +8.47% in the last 52 weeks. The beta is 0.62, so BeiGene's price volatility has been lower than the market average.

Beta (5Y) 0.62
52-Week Price Change +8.47%
50-Day Moving Average n/a
200-Day Moving Average n/a
Relative Strength Index (RSI) n/a
Average Volume (20 Days) 679

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 3.43

Income Statement

In the last 12 months, BeiGene had revenue of 3.35 billion and -854.42 million in losses. Loss per share was -8.19.

Revenue 3.35B
Gross Profit 2.80B
Operating Income -886.48M
Pretax Income -801.31M
Net Income -854.42M
EBITDA -794.98M
EBIT -886.48M
Loss Per Share -8.19
Full Income Statement

Balance Sheet

The company has 2.71 billion in cash and 1.05 billion in debt, giving a net cash position of 1.66 billion.

Cash & Cash Equivalents 2.71B
Total Debt 1.05B
Net Cash 1.66B
Net Cash Per Share n/a
Equity (Book Value) 3.45B
Book Value Per Share 32.32
Working Capital 1.89B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -649.87 million and capital expenditures -541.71 million, giving a free cash flow of -1.19 billion.

Operating Cash Flow -649.87M
Capital Expenditures -541.71M
Free Cash Flow -1.19B
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 83.67%, with operating and profit margins of -26.45% and -25.50%.

Gross Margin 83.67%
Operating Margin -26.45%
Pretax Margin -23.91%
Profit Margin -25.50%
EBITDA Margin -23.72%
EBIT Margin -26.45%
FCF Margin -35.56%

Dividends & Yields

BeiGene does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield 0.07%
Shareholder Yield 0.07%
Earnings Yield n/a
FCF Yield n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

BeiGene has an Altman Z-Score of 2.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.96
Piotroski F-Score n/a